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patients must be <18 years of age, weight ≥6 kg, and have confirmed
B-NHL relapsed or refractory to ≥1 prior lines of therapy. Karnofsky
(age ≥16 years) or Lansky (age <16 years) performance status must be
≥60. Patients must not have active central nervous system disease
involvement before infusion or prior treatment with any anti-CD19 or
gene therapy. Prior therapy can include systemic therapies and alloge-
neic or autologous hematopoietic stem cell transplant (HSCT) pro-
vided it occurred >3 months prior to screening. The primary endpoint
of this study is overall response rate by International Pediatric NHL
Response Criteria and Lugano 2014 criteria. Secondary outcomes
include duration of response, event-free survival, relapse-free survival,
progression-free survival, overall survival, pharmacokinetics, immuno-
genicity, frequency of post-tisagenlecleucel SCT, and biomarkers. Esti-
mated enrollment for this study is 35 patients (at least 26 infused and
evaluable).
Clinical trial information: NCT03610724.
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Background: Tisagenlecleucel is an anti-CD19 chimeric antigen
receptor-T cell (CAR-T) therapy that was approved in 2017 for the
treatment of pediatric and young adult patients up to 25 years of age
with relapsed/refractory (r/r) B-cell acute lymphoblastic leukemia
(Maude et al. NEJM. 2018), as well as for the treatment of adult
patients with r/r diffuse large B-cell lymphoma in 2018 (Schuster et al.
NEJM. 2018). Follicular lymphoma (FL) is the second most common
non-Hodgkin lymphoma in the Western hemisphere, with limited
treatment options in patients refractory to or relapsing after standard
therapies. In a phase 2a study of patients with r/r CD19+ lymphomas,
10 of 14 (71%) patients with r/r FL treated with tisagenlecleucel
achieved a durable complete remission at a median follow-up of
28.6 months (Schuster et al. NEJM. 2017). Here we introduce ELARA
(NCT03568461), a phase 2 study evaluating the efficacy and safety of
tisagenlecleucel in patients with r/r FL.
Methods: ELARA is a phase 2, single-arm, multicenter, open label
trial. Eligible patients must be ≥18 years of age, have radiographi-
cally measurable grade 1, 2, or 3A FL that is refractory to a second
or later line of systemic therapy (including an anti-CD20 antibody
and an alkylator), or relapsed within 6 months after completion of
a second or later line of systemic therapy, or relapsed during anti-
CD20 antibody maintenance (following ≥2 lines of therapy as
above) or within 6 months after maintenance completion, or
relapsed after autologous hematopoietic stem cell transplant
(HSCT). Patients with central nervous system involvement, or those
who received prior anti-CD19 therapy, gene therapy, adoptive
T-cell therapy, or allogeneic HSCT are not eligible. The primary
endpoint of this study is complete response rate based on Lugano
classification response criteria. Secondary outcomes include overall
response rate, duration of response, overall survival, cellular kinet-
ics, immunogenicity, safety, and patient-reported outcomes. Esti-
mated enrollment for this study is 113 patients. The study is
currently open to patient enrollment.
Clinical trial information: NCT03568461.
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Background: Tisagenlecleucel is an anti-CD19 chimeric antigen
receptor-T cell therapy approved for pediatric patients with r/r
B-cell acute lymphoblastic leukemia in 2017 (Maude et al. NEJM.
2018) and adult patients with relapsed/refractory diffuse large B-cell
lymphoma (r/r DLBCL) in 2018 (Schuster et al. NEJM. 2018). The
JULIET trial showed efficacy and safety of tisagenlecleucel in r/r
DLBCL; subgroup analyses suggested an association between PD-1/
PD-L1 interaction and lack of response (Agoulnik et al. EHA. 2018).
Pembrolizumab after tisagenlecleucel has shown clinical activity in
r/r DLBCL (Chong et al. Blood. 2017). We introduce PORTIA, a trial
investigating safety and efficacy of tisagenlecleucel plus
pembrolizumab in r/r DLBCL.
Methods: PORTIA is a phase 1b, multicenter, open-label, dose-
timing and dose-expansion trial. Optimal timing of pembrolizumab
administration will be based on the estimation of probability of
dose-limiting toxicities (DLTs). A 2-parameter Bayesian Logistic
Regression Method guided by the Escalation with Overdose Control
principle will guide dose-timing selection together with review of
accumulating safety and cellular kinetic data. Eligible patients must
be ≥18 years old and have a confirmed diagnosis of r/r DLBCL with
measurable disease and no active central nervous system disease;
received ≥2 prior lines of therapy, including anti-CD20 and
anthracycline-based chemotherapy, relapsing to or not eligible for
autologous stem cell transplant (SCT); ECOG performance status
must be 0 or 1. Patients treated with prior allogeneic SCT or anti-
CD3, anti-CD19, or checkpoint inhibitor therapy are excluded.
Primary endpoints are the proportion of patients receiving
pembrolizumab per protocol schedule, the incidence of DLTs in the
dose-timing selection phase, and overall response rate in the dose-
expansion phase. Secondary outcomes include duration of response,
progression-free survival, overall survival, safety, cellular kinetics,
and immunogenicity. Estimated enrollment is 8-12 patients in the
dose-timing and 12-16 patients in the dose-expansion phase. Dose-
timing selection is currently ongoing. The first cohort of 4 patients
receiving pembrolizumab at day 15 after tisagenlecleucel infusion
has been completed.
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